MUP-PCL-TEO-PVA Bilayer Nanofiber Scaffold Incorporated with Mupirocin and Thyme Essential Oil for Synergistic Activity Against Bacterial Wound Infections.

Q3 Pharmacology, Toxicology and Pharmaceutics

Fabad Journal of Pharmaceutical Sciences Pub Date : 2024-01-19 DOI:10.55262/fabadeczacilik.1346469

Kisan Jadhav, Shivani Gharat, Shradha B Adhalrao

{"title":"MUP-PCL-TEO-PVA Bilayer Nanofiber Scaffold Incorporated with Mupirocin and Thyme Essential Oil for Synergistic Activity Against Bacterial Wound Infections.","authors":"Kisan Jadhav, Shivani Gharat, Shradha B Adhalrao","doi":"10.55262/fabadeczacilik.1346469","DOIUrl":null,"url":null,"abstract":"Electrospinning process was used for constructing the bilayer nanofibers scaffold using drug and oil \ncontaining polymeric emulsion for synergistic activity against bacterial wound infections. The \ncharacterization was done for morphology, chemical composition, thermal behaviour, porosity, \nswelling ratio, drug release, in vitro permeation, ex vivo studies, and antimicrobial activity. In vitro \ndrug permeation study, exhibited initial rapid release of MUP upto 53% in the first 6 hrs and \nfollowing a slower sustained release achieving 92.17% drug release in 72 hours whereas TEO showed \nrelease in 10 hrs with initial burst release followed by sustained release achieving 85.45% release. The \nex vivo skin permeation data revealed greater permeability compared to conventional films. \nAntibacterial activity of the bilayer nanofiber scaffold was found to be greater than that of single layer \nMUP and TEO scaffold as zone of inhibition of MUP-PCL-TEO-PVA bilayer scaffold was greater \nwhich indicates the synergistic activity of MUP and TEO.","PeriodicalId":36004,"journal":{"name":"Fabad Journal of Pharmaceutical Sciences","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fabad Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55262/fabadeczacilik.1346469","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Electrospinning process was used for constructing the bilayer nanofibers scaffold using drug and oil containing polymeric emulsion for synergistic activity against bacterial wound infections. The characterization was done for morphology, chemical composition, thermal behaviour, porosity, swelling ratio, drug release, in vitro permeation, ex vivo studies, and antimicrobial activity. In vitro drug permeation study, exhibited initial rapid release of MUP upto 53% in the first 6 hrs and following a slower sustained release achieving 92.17% drug release in 72 hours whereas TEO showed release in 10 hrs with initial burst release followed by sustained release achieving 85.45% release. The ex vivo skin permeation data revealed greater permeability compared to conventional films. Antibacterial activity of the bilayer nanofiber scaffold was found to be greater than that of single layer MUP and TEO scaffold as zone of inhibition of MUP-PCL-TEO-PVA bilayer scaffold was greater which indicates the synergistic activity of MUP and TEO.

查看原文本刊更多论文

加入莫匹罗星和百里香精油的 MUP-PCL-TEO-PVA 双层纳米纤维支架对细菌性伤口感染具有协同作用。

利用电纺丝工艺，使用药物和含油聚合物乳液构建了双层纳米纤维支架，以增强抗细菌伤口感染的活性。对纳米纤维的形态、化学成分、热性能、孔隙率、膨胀率、药物释放、体外渗透、体内外研究和抗菌活性进行了表征。体外药物渗透研究显示，MUP 在最初 6 小时内的快速释放率高达 53%，随后出现了较慢的持续释放，72 小时内药物释放率达到 92.17%，而 TEO 则在 10 小时内出现释放，最初为爆发释放，随后出现持续释放，释放率达到 85.45%。体外皮肤渗透数据显示，与传统薄膜相比，其渗透性更高。双层纳米纤维支架的抗菌活性高于单层 MUP 和 TEO 支架，因为 MUP-PCL-TEO-PVA 双层支架的抑菌区更大，这表明 MUP 和 TEO 具有协同活性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Fabad Journal of Pharmaceutical Sciences Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

0.80

自引率

0.00%

发文量

期刊介绍： The FABAD Journal of Pharmaceutical Sciences is published triannually by the Society of Pharmaceutical Sciences of Ankara (FABAD). All expressions of opinion and statements of supposed facts appearing in articles and/or advertisiments carried in this journal are published on the responsibility of the author and/or advertiser, anda re not to be regarded those of the Society of Pharmaceutical Sciences of Ankara. The manuscript submitted to the Journal has the requirement of not being published previously and has not been submitted elsewhere. Manuscripts should be prepared in accordance with the requirements specified as given in detail in the section of “Information for Authors”. The submission of the manuscript to the Journal is not a condition for acceptance; articles are accepted or rejected on merit alone. All rights reserved.